Investment managers back greater transparency of clinical trialsBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4002 (Published 23 July 2015) Cite this as: BMJ 2015;351:h4002
- Nigel Hawkes
Pension funds and asset managers with more than €3.5 trillion (£2.45trn; $3.83trn) of assets under management have put their weight behind the AllTrials (alltrials.net) campaign, which is seeking greater transparency in the conduct of clinical trials.
Arguing that investors often commit their money to drug company shares on the basis of trials completed long before the drugs are marketed, the 85 strong investor group said that clarity and transparency are vital if investors are not to be misled.
Helena Viñes Fiestas, of BNP Paribas, which helped …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial